BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 12018633)

  • 1. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
    Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
    J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.
    Greenbaum LA; Grenda R; Qiu P; Restaino I; Wojtak A; Paredes A; Benador N; Melnick JZ; Williams LA; Salusky IB
    Pediatr Nephrol; 2005 May; 20(5):622-30. PubMed ID: 15785941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012.
    Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS;
    PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients.
    Buargub MA; Nabulsi MF; Shafeh TA
    Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):401-7. PubMed ID: 16970264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of parathyroid hormone concentration in hemodialysis patients.
    Li J; Molnar MZ; Zaritsky JJ; Sim JJ; Streja E; Kovesdy CP; Salusky I; Kalantar-Zadeh K
    Nephrol Dial Transplant; 2013 Jun; 28(6):1516-25. PubMed ID: 23348879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study.
    Block GA; Hulbert-Shearon TE; Levin NW; Port FK
    Am J Kidney Dis; 1998 Apr; 31(4):607-17. PubMed ID: 9531176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sevelamer hydrochloride improves hyperphosphatemia in hemodialysis patients with low bone turnover rate and low intact parathyroid hormone levels.
    Kokuho T; Toya Y; Kawaguchi Y; Tamura K; Iwatsubo K; Dobashi Y; Nakazawa A; Takeda H; Iwatsubo M; Hirawa N; Yasuda G; Ohnishi T; Umemura S
    Ther Apher Dial; 2007 Dec; 11(6):442-8. PubMed ID: 18028171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K/DOQI guideline requirements for calcium, phosphate, calcium phosphate product, and parathyroid hormone control in dialysis patients: can we achieve them?
    Wei M; Taskapan H; Esbaei K; Jassal SV; Bargman JM; Oreopoulos DG
    Int Urol Nephrol; 2006; 38(3-4):739-43. PubMed ID: 17160632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis.
    Nasri H; Baradaran A; Naderi AS
    Acta Med Austriaca; 2004 Aug; 31(3):67-72. PubMed ID: 15515479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal ostodystrophy during the developing stage of maintenance dialysis in Transylvania. Early development of periarticular calcifications and beta 2 microglobulin amyloidosis in spite of a relatively good prevention of secondary hyperparathyroidism.
    Oprisiu R; Bolosiu H; Boca I; Theodoru C; Elefterescu R; Brazier M; el Esper I; Leflon P; Ledeme C; Fournier A; Heinze V
    Ann Med Interne (Paris); 1998 Mar; 149(2):67-75. PubMed ID: 11490527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis.
    Avila-Díaz M; Matos M; García-López E; Prado MD; Castro-Vázquez F; Ventura MD; González E; Amato D; Paniagua R
    Perit Dial Int; 2006; 26(1):78-84. PubMed ID: 16538879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum magnesium concentration is an independent predictor of parathyroid hormone levels in peritoneal dialysis patients.
    Navarro JF; Mora C; Macia M; Garcia J
    Perit Dial Int; 1999; 19(5):455-61. PubMed ID: 11379859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.
    Taniguchi M; Fukagawa M; Fujii N; Hamano T; Shoji T; Yokoyama K; Nakai S; Shigematsu T; Iseki K; Tsubakihara Y;
    Ther Apher Dial; 2013 Apr; 17(2):221-8. PubMed ID: 23551679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 22-oxacalcitriol and calcitriol on PTH secretion and bone mineral metabolism in a crossover trial in hemodialysis patients with secondary hyperparathyroidism.
    Ogata H; Koiwa F; Shishido K; Takahashi K; Ito H; Kinugasa E; Taguchi S
    Ther Apher Dial; 2007 Jun; 11(3):202-9. PubMed ID: 17498002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.